Bharat Biotech on Thursday announced "successful completion" of volunteer enrolment for Phase-3 clinical trials of its indegenously manufactures Covid-19 vaccine 'Covaxin.'
"COVAXIN successfully completes Phase 3 clinical trials enrolment of 25,800 volunteers," informed Suchitra Ella Joint Managing Director Bharat Biotech International Limited, reports the Mint.
"We sincerely express our gratitude to clinical trial sites, Principle Investigators & healthcare workers for their relentless support and trust in our Public-Private Partnership vaccine discovery. My deep appreciation to all the volunteers for reposing trust and expressing Pro Vaccine Public Health Volunteerism in the Phase-3 Clinical Trials of India's 1' fully indigenous Covid-19 Vaccine," she added.
The announcement came days after the Hyderabad-based vaccine manufacturer announced successful recruitment of 23,000 volunteers and continued progress towards achieving the goal of 26,000 participants for the phase 3 trial of its coronavirus vaccine candidate Covaxin in India.